CO5580740A2 - Formulacion solida para utilizar como medicamento a base de de un derivado de piperazinurea - Google Patents
Formulacion solida para utilizar como medicamento a base de de un derivado de piperazinureaInfo
- Publication number
- CO5580740A2 CO5580740A2 CO04044345A CO04044345A CO5580740A2 CO 5580740 A2 CO5580740 A2 CO 5580740A2 CO 04044345 A CO04044345 A CO 04044345A CO 04044345 A CO04044345 A CO 04044345A CO 5580740 A2 CO5580740 A2 CO 5580740A2
- Authority
- CO
- Colombia
- Prior art keywords
- acid
- solid formulation
- glyceryl
- stearate
- polymer matrix
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
1.- Formulación sólida para utilizar como medicamento que contiene (2R)-1-((4-cloro-2-(ureido)fenoxi)metil) carbonil -2-metil-4-(4-fluoro-bencil)-piperazina o una de sus sales caracterizada porque contiene adicionalmente una matriz polimérica, un ácido orgánico, un lubricante y uno o varios excipientes y porque el 90% de los tamaños de partículas de las mezclas en polvo se ubican en el rango de 0,1 a 750 µm.2.- Formulación sólida para utilizar como medicamento de acuerdo a la reivindicación 1, en la que la matriz polimérica se seleccionó del grupo compuesto por derivados de celulosa, derivados acrílicos, polímeros vinílicos, polianhídridos, poliéster poliortoéster, poliuretanos, policarbonatos, polifosfacenos, poliacetales, polisacáridos, éster de azúcar, dietilenglicol-monoetiléter, dietilenglicol-monopalmito-estearato, etilenglicol-monopalmitoestearato, behenatos de glicerilo y dibehenatos de glicerilo, diestearatos de glicerilo y palmitoestearatos de glicerilo, monooleato de glicerilo 40, monoestearato de glicerilo 40-55, laurato de macrogolglicerilo, estearato de macrogolglicerilo, monopalmito-estearato de propilenglicol, quitosán, galactomanano, pectina, goma laca y alginatos.3.- Formulación sólida para utilizar como medicamento de acuerdo a la reivindicación 1 ó 2, en la que la matriz polimérica está compuesta por una mezcla de polivinilpirrolidona soluble en agua y polivinilacetato insoluble en agua.4.- Formulación sólida para utilizar como medicamento de acuerdo a una de las reivindicaciones 1-3, en la que la matriz polimérica presenta la siguiente composición: 80% de acetato de polivinilo, 19% polivinilpirrolidona, 0,8% de laurilsulfato sódico y 0,2% de dióxido de silicio.5.- Formulación sólida para utilizar como medicamento de acuerdo a una de las reivindicaciones 1-4, en la que se seleccionó el ácido orgánico del grupo compuesto por ácido fumárico, ácido cítrico, citrato trisódico, hidrocitrato sódico, ácido ascórbico, ácido maleico, anhídrido maleico, ácido tartárico, ácido adípico, hidrofosfato sódico, ácido succínico, ácido glutárico, anhídrido glutárico, sorbato de potasio y ácido sórbico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10152351A DE10152351B4 (de) | 2001-10-18 | 2001-10-18 | Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5580740A2 true CO5580740A2 (es) | 2005-11-30 |
Family
ID=7703496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04044345A CO5580740A2 (es) | 2001-10-18 | 2004-05-13 | Formulacion solida para utilizar como medicamento a base de de un derivado de piperazinurea |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1435917A1 (es) |
| JP (1) | JP2005506365A (es) |
| KR (1) | KR20040047920A (es) |
| CN (1) | CN1571660A (es) |
| AR (1) | AR037111A1 (es) |
| AU (1) | AU2002333896B2 (es) |
| BR (1) | BR0213340A (es) |
| CA (1) | CA2463951A1 (es) |
| CO (1) | CO5580740A2 (es) |
| DE (1) | DE10152351B4 (es) |
| EC (1) | ECSP045108A (es) |
| HR (1) | HRP20040435A2 (es) |
| IL (1) | IL161166A0 (es) |
| MX (1) | MXPA04003522A (es) |
| NO (1) | NO20042022L (es) |
| NZ (1) | NZ532287A (es) |
| PE (1) | PE20030472A1 (es) |
| PL (1) | PL367987A1 (es) |
| RS (1) | RS32204A (es) |
| RU (1) | RU2311172C2 (es) |
| UY (1) | UY27500A1 (es) |
| WO (1) | WO2003035037A1 (es) |
| ZA (1) | ZA200403781B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1990468A (zh) | 2001-06-27 | 2007-07-04 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| EP1749519A1 (de) * | 2005-08-05 | 2007-02-07 | Schering Aktiengesellschaft | Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit |
| ES2572180T3 (es) * | 2006-04-26 | 2016-05-30 | Alphapharm Pty Ltd | Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada |
| DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
| KR101654582B1 (ko) | 2016-05-12 | 2016-09-06 | 그린로드(주) | 원뿔형 부유 고분자 필터, 및 그의 제조장치 및 제조방법, 및 그를 포함하는 수처리 필터 |
| RU2729223C1 (ru) * | 2020-05-13 | 2020-08-05 | Мераб Георгиевич Чикобава | Дозированная форма для амплификации нуклеиновых кислот |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207665B1 (en) * | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
| ATE337307T1 (de) * | 1998-02-05 | 2006-09-15 | Pfizer Prod Inc | Neue dihydroxyhexansäurederivate |
| EP1970052A2 (en) * | 1999-02-09 | 2008-09-17 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
-
2001
- 2001-10-18 DE DE10152351A patent/DE10152351B4/de not_active Expired - Fee Related
-
2002
- 2002-10-07 MX MXPA04003522A patent/MXPA04003522A/es unknown
- 2002-10-07 BR BR0213340-7A patent/BR0213340A/pt not_active IP Right Cessation
- 2002-10-07 KR KR10-2004-7005591A patent/KR20040047920A/ko not_active Application Discontinuation
- 2002-10-07 NZ NZ532287A patent/NZ532287A/en unknown
- 2002-10-07 WO PCT/EP2002/011229 patent/WO2003035037A1/de not_active Application Discontinuation
- 2002-10-07 IL IL16116602A patent/IL161166A0/xx unknown
- 2002-10-07 RS YU32204A patent/RS32204A/sr unknown
- 2002-10-07 AU AU2002333896A patent/AU2002333896B2/en not_active Ceased
- 2002-10-07 RU RU2004115328/15A patent/RU2311172C2/ru not_active IP Right Cessation
- 2002-10-07 CA CA002463951A patent/CA2463951A1/en not_active Abandoned
- 2002-10-07 JP JP2003537604A patent/JP2005506365A/ja active Pending
- 2002-10-07 EP EP02801884A patent/EP1435917A1/de not_active Withdrawn
- 2002-10-07 CN CNA02820512XA patent/CN1571660A/zh active Pending
- 2002-10-07 PL PL02367987A patent/PL367987A1/xx not_active Application Discontinuation
- 2002-10-17 PE PE2002001027A patent/PE20030472A1/es not_active Application Discontinuation
- 2002-10-17 UY UY27500A patent/UY27500A1/es not_active Application Discontinuation
- 2002-10-18 AR ARP020103929A patent/AR037111A1/es unknown
-
2004
- 2004-05-13 CO CO04044345A patent/CO5580740A2/es not_active Application Discontinuation
- 2004-05-14 NO NO20042022A patent/NO20042022L/no not_active Application Discontinuation
- 2004-05-17 HR HR20040435A patent/HRP20040435A2/hr not_active Application Discontinuation
- 2004-05-17 ZA ZA200403781A patent/ZA200403781B/en unknown
- 2004-05-17 EC EC2004005108A patent/ECSP045108A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040047920A (ko) | 2004-06-05 |
| JP2005506365A (ja) | 2005-03-03 |
| WO2003035037A1 (de) | 2003-05-01 |
| NZ532287A (en) | 2007-04-27 |
| RS32204A (en) | 2006-10-27 |
| PL367987A1 (en) | 2005-03-21 |
| IL161166A0 (en) | 2004-08-31 |
| PE20030472A1 (es) | 2003-06-16 |
| DE10152351A1 (de) | 2003-05-08 |
| DE10152351B4 (de) | 2005-09-22 |
| RU2004115328A (ru) | 2005-06-10 |
| NO20042022L (no) | 2004-05-14 |
| ZA200403781B (en) | 2004-11-29 |
| ECSP045108A (es) | 2004-06-28 |
| UY27500A1 (es) | 2003-06-30 |
| BR0213340A (pt) | 2004-10-05 |
| AU2002333896B2 (en) | 2007-07-26 |
| AR037111A1 (es) | 2004-10-20 |
| AU2002333896A2 (en) | 2003-05-06 |
| RU2311172C2 (ru) | 2007-11-27 |
| CA2463951A1 (en) | 2003-05-01 |
| CN1571660A (zh) | 2005-01-26 |
| EP1435917A1 (de) | 2004-07-14 |
| MXPA04003522A (es) | 2004-07-23 |
| HRP20040435A2 (en) | 2005-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG106439A (en) | Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative | |
| AR088808A2 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| AR084101A2 (es) | Comprimido de carga de droga alta y proceso para su preparacion | |
| AR018143A1 (es) | Formulacion para preparar un comprimido de desintegracion rapida, comprimidos de desintegracion rapida, especialmente comprimidos de desintegracionrapida en la boca | |
| ATE493973T1 (de) | Irbesartan enthaltende pharmazeutische zusammensetzung | |
| KR950007841A (ko) | 트라마돌 염을 함유하는 서방성 약물 제제 | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| TW200503775A (en) | Pharmaceutical composition and method for treating | |
| PE20040499A1 (es) | Nuevas formulaciones de liberacion prolongada inyectables | |
| DE60131088D1 (de) | Gelierende wässrige pharmazeutische zusammensetzungen | |
| WO2003105767A3 (en) | ANTIFUNGAL PARENTERAL PRODUCTS | |
| AR006598A1 (es) | "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación" | |
| ATE386725T1 (de) | Heterocyclylverbindungen | |
| ATE500216T1 (de) | Tricyclische derivate oder pharmazeutisch unnbedenkliche salze davon, deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten | |
| ECSP077262A (es) | Composicion antihistaminica | |
| CO5580740A2 (es) | Formulacion solida para utilizar como medicamento a base de de un derivado de piperazinurea | |
| HUP0103431A2 (hu) | 5-HT4 receptor agonista vagy antagonista hatóanyagot tartalmazó, orális gyógyászati készítmény | |
| CO5261595A1 (es) | Composiciones farmaceuticas que contienen una combinacion de salmeterol e ipratropium | |
| NO950134L (no) | Formuleringer for oralt administrerte farmasöytiske midler | |
| EP2804597A1 (en) | Aqueous paracetamol composition for injection | |
| RU2008147216A (ru) | Жидкая лекарственная композиция | |
| JP5650397B2 (ja) | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| SG145717A1 (en) | Composition for releasing a weak base for an extended period of time | |
| ES2150404T1 (es) | Composiciones farmaceuticas de tizoxanida y nitozoxanida. | |
| JP2018203728A (ja) | 視覚機能の再活性化用眼科組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |